Targeting Inflammation in Atherosclerosis: CANTOS Trial
Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US) provides us with an overview of the CANTOS main trial results and updated results from the ACC 2022.
Read MoreRead Less
Supported by an unrestricted educational grant from NOVO NORDISK A/S.
Read MoreRead Less
Join Dr Peter Libby (Brigham and Women’s Hospital, Boston, US) as he talks us through the RESCUE trial design and results in this short podcast.
Read More
All Episodes
Is there enough evidence to support the prognostic value of coronary physiology measurements in pre-and post-PCI settings? Is post-PCI FFR ready for clinical practice?
Today's episode features co-hosts Dr Peter Ong and Dr Andreas Seitz (Robert-Bosch Hospital, Stuttgart, DE) who together summarise the main results from the TARGET FFR and DEFINE-FLOW trials that were presented at TCT Connect 2020 and published recently in ECR journal, in the context of the existing literature.
Read More
Today's episode features co-hosts Dr Peter Ong and Dr Andreas Seitz (Robert-Bosch Hospital, Stuttgart, DE) who together summarise the main results from the TARGET FFR and DEFINE-FLOW trials that were presented at TCT Connect 2020 and published recently in ECR journal, in the context of the existing literature.
Did you know that CV disease is the leading cause of death in women and that women are more likely to die of heart disease compared to men? Dr Erin Michos (John Hopkins Uni, US) and Dr Martha Gulati (Uni of Arizona, US) join us on the inaugural episode of the ECR podcast series to discuss issues surrounding women in heart disease. Together they explore a variety of topics that are addressed in the latest special focus issue in the European cardiology Review journal.
Read More
Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam for a deep dive into the late-breaking data presented at ACC.24.
Read More
What’s hot at ACC.24?
Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) to learn more about this year’s key late-breaking and featured science trials that have the potential to shape practice and research.
Read More
Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) to learn more about this year’s key late-breaking and featured science trials that have the potential to shape practice and research.
In this episode of the Radcliffe Podcast, we are joined by Dr Raymond Pranata, Dr Mohammad Iqbal and Dr Giky Karwiky (Hasan Sadikin General Hospital, Bandung, Indonesia) as they discuss their recently published systematic review and meta-analysis of very-high-power short-duration ablation as compared to conventional ablation for the treatment of pulmonary vein isolation in atrial fibrillation.
Read More
Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the latest late-breaking science data from AHA Scientific Sessions 2023.
They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research.
Read More
They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research.
Join interventional cardiologists, Prof Nicolas Van Mieghem and Dr Joost Daemen from the Thoraxcenter as they unpack the most impactful late-breaking clinical trials and science data from this year's Transcatheter Cardiovascular Therapeutics Conference.
Dive into this practical and engaging discussion and learn more about the latest data for practice and for research.
Read More
Dive into this practical and engaging discussion and learn more about the latest data for practice and for research.